MedPath

Multicenter phase II trial to Prevent Docetaxel-Induced Nail change using a Frozen Glove with docetaxel (T) and cyclophosphamide(C) as adjuvant chemotherapy for patients with high risk, node negative, early stage breast cancer: Tokai Breast Cancer Clinical Research Group (TBCRG) 03 trial

Phase 2
Conditions
Breast cancer
Registration Number
JPRN-UMIN000000806
Lead Sponsor
Tokai Breast Cancer Clinical Research Group (TBCRG)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1.As neoadjuvant and adjuvant therapy , treated hormone therapy and chemotherapy 2.HER2 / neu gene overexpressed or amplified 3.A history of whitlow and cold allergy 4.Bilateral breast cancer and Inflammatory breast cancer 5.Uncontrolled medical conditions 6.Hepatitis B 7.A history of other malignancies within the last 5 years except for adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix 8.Sever infection 9.Peripheral neuropathy 10.Pleural or pericardial effusion requiring treatment 11.Pregnant or lactating women and women of child bearing potential not using contraception. 12.Grade2-4 Severe peripheral edema. 13.Significant interstitial pneumonia or pulmonary fibrosis by CT scan or X-ray 14.A history of hypersensitivity reaction to drugs formulated with Polysorbate 80 15.Severe psychiatric disorders 16.Patients judged by the investigator to be unfit to be enrolled into the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Prevention of nail change by frozen glove
Secondary Outcome Measures
NameTimeMethod
Safety, feasibility
© Copyright 2025. All Rights Reserved by MedPath